Danaher Corp

Research Danaher Corp (DHR) on Bullrun: valuation model: 10.4% overvalued, market cap USD 154.50B, P/E 39.0, dividend yield 0.7%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

Bullrun's latest valuation model marks Danaher Corp as 10.4% overvalued; latest market cap is USD 154.50B; P/E is 39.0; dividend yield is 0.7%.

Peer valuation comparison

Latest P/E is 39.03x versus a Healthcare sector median of 24.64x (58.4% above).

Latest dividend yield is 0.69% versus a Healthcare sector median of 1.83% (62.2% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 24.57BUSD 3.61BUSD 5.26B59.1%5.05USD 4.62BUSD 18.42BUSD 52.53B
FY2024USD 23.88BUSD 3.90BUSD 5.30B59.5%5.29USD 2.08BUSD 16.01BUSD 49.54B
FY2023USD 23.89BUSD 4.76BUSD 5.78B58.7%6.38USD 5.86BUSD 18.40BUSD 53.49B
FY2022USD 26.64BUSD 7.21BUSD 7.40B60.8%9.66USD 6.00BUSD 19.68BUSD 50.08B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-09USD 154.50B39.00.7%1.52
20252025-12-31USD 161.82B45.30.6%1.28
20242024-12-31USD 165.07B43.40.5%1.08
20232023-12-29USD 170.94B29.30.4%0.99
20222022-12-30USD 171.29B26.00.4%0.88
20212021-12-31USD 208.55B33.90.3%0.76

Dividend history

Latest trailing dividend snapshot: annual dividend/share 1.52 USD, yield 0.7%.

YearDividends/share
FY20251.28 USD
FY20241.08 USD
FY20230.99 USD
FY20220.88 USD

About Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services;

ETFs that hold Danaher Corp

Danaher Corp is one of the ten largest holdings of 16 ETFs that investors in Europe can buy. The 8 most traded of them:

ETFWeightTER
VanEck Morningstar US ESG Wide Moat UCITS ETF2.71%0.49%
Amundi MSCI ACWI SRI Climate Paris Aligned UCITS ETF DR - USD (A)1.08%0.20%
BNP Paribas Easy MSCI World SRI PAB UCITS ETF EUR Capitalisation1.19%0.25%
iShares AI Adopters & Applications UCITS ETF USD (Acc)1.85%0.35%
VanEck Morningstar Global Wide Moat UCITS ETF A USD2.25%0.52%
Invesco MSCI USA ESG Climate Paris Aligned UCITS ETF2.97%0.09%
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C USD Acc4.46%0.30%
L&G S&P 100 Equal Weight $1.10%0.19%

Compare every fund on the same index:

MSCI World SRI ETFs MSCI ACWI SRI ETFs

Related stock research

United States stocks United States Healthcare stocks A-Z stock index

Other Healthcare stocks

Agilent Technologies Inc (A) Adaptive Biotechnologies Corp (ADPT) Advanced Biomed Inc (ADVB) Biodesix Inc (BDSX) BioAffinity Technologies Inc (BIAF) Billiontoone Inc - Class A (BLLN) Caredx Inc (CDNA) Charles River Laboratories International Inc (CRL) Castle Biosciences Inc (CSTL) Quest Diagnostics Inc (DGX) Fulgent Genetics Inc (FLGT) Guardant Health Inc (GH)

Frequently asked questions

Is Danaher Corp overvalued or undervalued?

Bullrun's valuation model currently marks Danaher Corp as 10.4% overvalued.

What is Danaher Corp's market cap?

Danaher Corp's market capitalization is USD 154.50B.

What is Danaher Corp's P/E ratio?

Danaher Corp's price-to-earnings (P/E) ratio is 39.0.

Does Danaher Corp pay a dividend?

Danaher Corp has a dividend yield of 0.7%.

What does Danaher Corp do?

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments.